A personalized mRNA cancer treatment may have crossed one of oncology’s hardest thresholds: a positive late-stage trial. But Moderna and Merck have announced the win before releasing the figures that would show just how big it is.

On Wednesday, the companies said their individualized treatment, intismeran—also called mRNA-4157—met key Phase 3 goals when paired with Merck’s Keytruda in patients whose stage IIB–IV melanoma had been surgically removed. The 1,137-patient trial compared the combination with Keytruda alone, with participants randomized two-to-one and treated for roughly a year.

The companies said the regimen significantly improved recurrence-free survival and distant metastasis-free survival, measures of how long patients remain free of returning cancer and of cancer spreading to distant sites. Yet they disclosed neither the size of those gains nor detailed survival results. Moderna and Merck said fuller data would be presented at an upcoming international medical conference.

The treatment is tailored to each patient: researchers identify up to 34 mutations unique to a tumour, encode them in synthetic mRNA and prompt the immune system to recognize those cancer-specific targets. Moderna and Merck have branded the approach a “neoantigen therapy,” a formulation that underscores its personalized design while avoiding politically charged language around mRNA vaccines.

The announcement follows encouraging Phase 2 results presented in June, which reported a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death. Moderna’s chief executive, Stéphane Bancel, called the Phase 3 readout “a pivotal moment for the field of cancer research.”¹

Outside specialists shared the excitement but stressed the limits of the release. Oxford cancer expert Lennard Lee said it was “the first positive Phase III trial of an individualized neoantigen therapy and an mRNA-based cancer treatment,” while warning that clinicians still need mature overall-survival, quality-of-life and subgroup data to determine who benefits most.¹

Investors responded quickly, with one report summarizing the market reaction as “Moderna shares double on skin cancer vaccine success.”² The scientific verdict, however, will depend on data still to come.